Navigate Fool.com
Will ALPMY beat
the market?



10.72 -0.12 (-1.06%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.69
Previous Close $10.83
Daily Range $10.68 - $10.71
52-Week Range $9.74 - $14.97
Market Cap $24.5B
P/E Ratio 0.00
Dividend (Yield) $0.00 (0.9%)
Volume 33,827
Average Daily Volume 102,129
Current FY EPS $0.48

How do you think ALPMY
will perform against the market?

Top ALPMY Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.

Why I Bought Exelixis

The author shares his opinion why the recent drop in Exelixis is an incredible buying opportunity.

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.

Was Medivation's Quarter a Disaster?

Medivation (MDVN) shares sank more than 10% on news of slowing sales growth for its prostate cancer drug Xtandi; however, an FDA decision and potential milestones may support the company into year end.

3 Investing Lessons From Dendreon

Dendreon, the maker of the the prostate cancer drug Provenge, has been marginalized by newer drugs from Johnson & Johnson, Medivation, and Astellas Pharma. What three valuable investing lessons can investors learn from Dendreon’s mistakes?

Uh Oh: Is This Cancer Highflyer In Your Account?

Can an EU Approval Save This Dying Biotech?

Dendreon, the creator of Provenge, recently rallied on an approval in Europe. However, is it too little, too late for this struggling company?

3 Humongous Health-Care Stocks This Week

These health care stocks made big gains to open the new month.

Optimer Pharmaceuticals Shares Soar... for the Right Price, That Is!

A curious quartet of potential bidders sends Optimer's share price soaring to the heavens, but is it really worth the risk?

See More ALPMY News...





Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks